Regulation News
Financial regulation news from the SEC, FINRA, and government agencies. Track policy changes, enforcement actions, and compliance updates affecting markets.
Ukrop's Recall: Six Meals Pulled Over Metal Fragments, Grocers See Minimal Financial Risk
Ukrop's Homestyle Foods recalls six ready-to-eat meals over aluminum slivers, affecting Kroger and Food Lion. Financial impact appears minimal; no injuries reported.
FDA Panel Nod Sparks $763M Value Shift Between Melanoma Drugmakers
Replimune (REPL) soared 107% after an FDA panel endorsed RP1, while Iovance (IOVA) tumbled 13%, shifting $763 million in market value between the two melanoma therapy rivals.
Student Loan Settlement Advances: $12B Distributed, Court Upholds Deadlines
A $23 billion student loan settlement advances with $12 billion already distributed, as the Ninth Circuit upholds key deadlines affecting over 170,000 borrowers.
Senate Crypto Bill Could Reshape Bank Fees and Stablecoin Rules
The Senate's CLARITY Act outlines new crypto banking revenue streams and stablecoin restrictions, with potential impacts on deposits and lending. Major banks could benefit, while community banks face risks.
Caterpillar Shares Slide on Baird Downgrade Amid Data Center Policy Concerns
Caterpillar shares dropped 6.4% after Baird downgraded the stock, citing policy risks from New York's data center permit limits that could impact demand.
Medicare Part D Subsidy Phaseout Widens Insurer Pricing Gap
CMS plans to end temporary Part D assistance after 2026, with 2027 bids up 23.7%. Insurers like Centene face enrollment risk as pricing gaps widen.
SpaceX Shares Dip as Orbital AI Faces Environmental Scrutiny
SpaceX shares slipped 1.3% pre-market as environmental scrutiny of its orbital AI project intensifies, with valuation at 81.9 times sales. Q2 results due Aug 4.
Crypto Stocks Slide as Senate Ethics Dispute Erodes Policy Gains
Shares of Coinbase, Circle, and Robinhood dropped 11% on average as the Clarity Act premium faded amid a Senate ethics dispute.
Hims & Hers Peptide Opportunity Tempered by FDA Timeline
Hims & Hers (HIMS) rose 3.4% after FDA advisers supported four unapproved peptides for compounding, but the final rule may take up to a year. Analysts estimate $440M in peptide sales by 2027.